Navigation Links
Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
Date:6/23/2008

MOUNTAIN VIEW, Calif., June 23 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it will present results of its Phase 2a clinical trial of Staccato(R) loxapine (AZ-104) for the treatment of migraine headache at the 50th Annual Scientific Meeting of the American Headache Society, which being held at the Marriott Boston Copley Place in Boston, MA. The oral platform abstract presentation, "Inhaled Loxapine, a Dopamine Antagonist, Reduces Headache Pain in Patients Having an Acute Migraine Attack", is scheduled for Friday, June 27, 2008 at 10:55 a.m. Eastern Time, and will be presented in University Hall. AZ-104 is a lower dose version of AZ-004, which is in Phase 3 clinical development for the treatment of acute agitation in patients with schizophrenia or bipolar disorder.

Alexza Pharmaceuticals is an emerging specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience.

Alexza has six product candidates in clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing and has completed the enrollment of its first Phase 3 clinical trial. AZ-001 (Staccato prochlorperazine) for the acute tre
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
2. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
3. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
4. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
7. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
8. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
9. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
10. Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration
11. Peregrine Pharmaceuticals Awarded Two New U.S. Patents Broadening Its Targeted Anti-Phospholipid Patent Portfolio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... FAIRFIELD, N.J. , Oct. 22, 2014 /PRNewswire/ ... a major transformation in the pain market, according ... Pain Insights, Inc., a firm providing market research ... management. Photo - http://photos.prnewswire.com/prnh/20141021/153440 ... a scheduling change for hydrocodone combination products from ...
(Date:10/22/2014)... Vernak, RPh, of Vernak Farms Pharmacy in ... George Roentsch Scholarship by the Professional Compounding Centers of ... Houston during PCCA,s International Seminar, held October ... independent pharmacist and PCCA member who embodies the innovative ... well-known pharmacist in the compounding community. ...
(Date:10/22/2014)... Oct. 22, 2014 AVACEN Medical announced today ... 510 (k) OTC clearance by the U.S. Food and ... be marketed over the Internet for: the temporary ... and minor strains and sprains . Logo ... 100 (MSRP $2495) is a sophisticated medical device incorporating ...
Breaking Medicine Technology:Hydrocodone: Rescheduled, Repositioned & Reinvented 2Hydrocodone: Rescheduled, Repositioned & Reinvented 3PCCA Awards Charlene Vernak, RPh, the George Roentsch Scholarship 2AVACEN Medical Announces FDA Clearance of First Medical Device with Internal Game Mode 2
... Calif., May 27 Epeius Biotechnologies,( http://www.epeiusbiotech.com ) ... Feasibility Study of sequential targeted gene delivery -- ... will be presented at the,ASCO meetings in Chicago ... 2008).,Rexin-G and Reximmune-C are pathotropic (disease-seeking) nanoparticles,bearing a ...
... in high risk node-negative, population to show ... BRIDGEWATER, N.J., May 27 Sanofi-aventis ... de Mama) announced today,that for women with ... (post surgery) with Taxotere(R) (docetaxel) Injection,Concentrate as ...
Cached Medicine Technology:TARGETED GENE DELIVERY SIGNALS CANCER VACCINATION IN VIVO: Intravenous Infusions of Rexin-G Followed by Reximmune-C Induce Tumor Necrosis and Recruitment of Tumor Infiltrating Lymphocytes in Cancerous Lesions (ASCO 2008) 2TARGETED GENE DELIVERY SIGNALS CANCER VACCINATION IN VIVO: Intravenous Infusions of Rexin-G Followed by Reximmune-C Induce Tumor Necrosis and Recruitment of Tumor Infiltrating Lymphocytes in Cancerous Lesions (ASCO 2008) 3Node-Negative Early Stage Breast Cancer Patients Benefit from Taxotere(R)-Based Chemotherapy 2Node-Negative Early Stage Breast Cancer Patients Benefit from Taxotere(R)-Based Chemotherapy 3Node-Negative Early Stage Breast Cancer Patients Benefit from Taxotere(R)-Based Chemotherapy 4Node-Negative Early Stage Breast Cancer Patients Benefit from Taxotere(R)-Based Chemotherapy 5
(Date:10/22/2014)... News) -- The United States is now mandating ... of West Africa land at one of five ... the virus. In a statement released Tuesday, ... percent of air passengers from Guinea, Liberia and ... five airports -- New York City,s Kennedy International ...
(Date:10/22/2014)... October 22, 2014 The ... which is dedicated to distribute health information technology ... delivery worldwide announced the development of six key ... expect when receiving healthcare. These are an expansion ... care: “providing care that is respectful of and ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 With the Affordable ... national survey by the American Institutes for Research (AIR) finds ... how to use health insurance, but 42 percent say they ... plan’s details before signing up for coverage. , The AIR ... only 20 percent able to calculate correctly how much they ...
(Date:10/22/2014)... Best Cheap Hosting USA is among the most distinguished ... announced that iPower ( http://www.best-cheap-hosting-usa.com/go/iPower/ ) is the best ... world. , “iPower is one of the most reliable ... kinds of useful products for new and old clients. ... service and a number of features which will appeal ...
(Date:10/22/2014)... 2014 Losing Weight Your Body’s Way , ... you in the face, it certainly can be difficult to ... body an extra favor by doing it the healthy way? ... Instead, listen to your body, exercise regularly, and choose foods ... to losing weight; you need to exercise more and eat ...
Breaking Medicine News(10 mins):Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 3Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 4Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2
... sign of additional illness, suggest experts, , MONDAY, June 29 ... episode of low blood sugar during a hospital stay was ... the hospital and up to a year later, new research ... with diabetes who were hospitalized for a variety of ailments, ...
... GAI-122, an investigational injectable nanoemulsion formulated with, ... significant, neuro-protection in multiple in vitro ... that this injectable nanoemulsion formulation has the potential to, ... MARKHAM, ON, June 29 /PRNewswire-FirstCall/ - AlphaRx Inc. (OTCBB: ...
... (NYSE: CSC ) announced today that Modern ... Wah, chief medical officer and vice president of CSC,s ... their annual ranking of the 50 Most Powerful Physician ... 4,300 physician executives for the fifth annual ranking. Of ...
... Action , , KIRKLAND, Wash., June 29 If ... may not include a public option for long-term care, the ... illnesses or disabilities. If you,re in the market for long-term ... Gott says no; there,s too much to lose and little ...
... The American Society of Anesthesiologists (ASA) continues to ignore ... of its newly launched ,Anesthesia & Me, site. , ... having anesthesia without brain monitors. Awareness under anesthesia affects 0.1% ... main ASA site distracts attention from the much larger public ...
... Florida,s First ... Palm Beach County Florida has become the first in the State to receive formal recognition as ... ... Now Urgent Care Medical Centers of Palm Beach County Florida has become the first in the ...
Cached Medicine News:Health News:Low Blood Sugar in Hospital Tied to Higher Death Risk for Diabetics 2Health News:Low Blood Sugar in Hospital Tied to Higher Death Risk for Diabetics 3Health News:AlphaRx and Gaia BioPharma Report Positive Efficacy Results in a Pre-Clinical Trial of GAI-122 Injectable Nano-emulsion for Post-operative Delirium 2Health News:CSC's Dr. Robert M. Wah Advances to Number Nine on 50 Most Powerful Physician Executives List 2Health News:Get Long-Term Care Protection Now; Don't Wait for Health Reform, Industry Leader Advises 2Health News:Get Long-Term Care Protection Now; Don't Wait for Health Reform, Industry Leader Advises 3Health News:American Society of Anesthesiologists Continues to Ignore Over Medication Risks 2Health News:MD Now Urgent Care Centers: First in Florida to Receive UCAOA Certification in Urgent Care 2Health News:MD Now Urgent Care Centers: First in Florida to Receive UCAOA Certification in Urgent Care 3
Latex agglutination slide test for the qualitative or quantitative determination of Cryptococcus neoformans antigen in CSF and serum....
... testing feature single-well ANA screen and ENA ... tests including dsDNA, and 6 individual ENA ... Scl-70 and Jo-1. In addition, our autoimmune ... products for Cardiolipins (IgA, IgG, IgM), Thyroglobulin, ...
... septicemia occur yearly in the U.S., with ... the organism and the determination of its ... Wampole ISOSTAT/ ISOLATOR Microbial System is a ... This technology is used to concentrate microorganisms ...
Hemagglutination slide test for the qualitative detection and quantitative determination of antibodies to streptococcal extracellular antigens in serum, plasma, or whole blood....
Medicine Products: